Clinical Trial Update: Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results update for GDC-0199 (venetoclax) in combination with obinutuzumab and ibrutinib in relapsed/refractory or previously untreated chronic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• GDC-0199 (venetoclax)
• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Kerry Rogers | Conditions: Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-27